Blog
RSS FeedPosted by Michael Wonder on 09 Aug 2018
Desperate plea for increased medicines funding for cancer sufferers
9 August 2018 - The Government must increase funding for medicines desperately needed by people with breast cancer and other ...
Posted by Michael Wonder on 09 Aug 2018
David Agnew appointed Chair of the CADTH Board of Directors
8 August 2018 - CADTH is pleased to announce the appointment of Mr. David Agnew to Chair of the CADTH ...
Posted by Michael Wonder on 09 Aug 2018
NICE changes its mind on Pfizer’s Besponsa
9 August 2018 - NICE has reversed its draft decision rejecting Pfizer’s Besponsa (inotuzumab ozogamicin) as a treatment for adults ...
Posted by Michael Wonder on 09 Aug 2018
'Balancing act' needed on unproven cancer drugs - Health Minister David Clark
9 August 2018 - The Health Minister is wary of side-stepping PHARMAC to buy newly developed cancer drugs, saying the ...
Posted by Michael Wonder on 08 Aug 2018
Lenvatinib mesylate and sorafenib tosylate for the treatment of patients with differentiated thyroid cancer after the use of radioactive iodine
8 August 2018 - NICE has published evidence-based recommendations on the use of lenvatinib mesylate (Lenvima) and sorafenib tosylate (Nexavar) ...
Posted by Michael Wonder on 08 Aug 2018
Ixekizumab for treatment of adults with active psoriatic arthritis
8 August 2018 - NICE has published evidence-based recommendations on the use of ixekizumab (Taltz) on the NHS for the ...
Posted by Michael Wonder on 08 Aug 2018
NICE publishes draft guidance on new use for lenvatinib mesylate
8 August 2018 - The Department of Health and Social Care has asked NICE to produce guidance on using lenvatinib mesylate ...
Posted by Michael Wonder on 08 Aug 2018
NICE publishes final appraisal determination for Alecensa
8 August 2018 - The determination relates to the use of alectinib hydrochloride for the first-line treatment of patients with untreated ...
Posted by Michael Wonder on 08 Aug 2018
UK unveils plans for bigger medicines price squeeze
7 August 2018 - Company payments to government would rise steeply to 2021. ...
Posted by Michael Wonder on 08 Aug 2018
Comparing the ICERs in medicine reimbursement submissions to NICE and PBAC—does the presence of an explicit threshold affect the ICER proposed?
8 August 2018 - The English NICE and the Australian PBAC require evidence that a new medicine represents value for money ...
Posted by Michael Wonder on 07 Aug 2018
NZ's cancer death rates worse than Australia's due to medicine inaccessibility - oncologist
7 August 2018 - The number of cancer deaths may increase if the country's approach to the disease isn't urgently ...
Posted by Michael Wonder on 07 Aug 2018
‘Survival of the richest’: Rich access drugs PHARMAC won’t fund
7 August 2018 - Oncologists including the cancer society's top doctor say the government's drug agency, PHARMAC, is failing to keep ...
Posted by Michael Wonder on 07 Aug 2018
Health insurance discounts will benefit only the young rich: consumer groups
7 August 2018 - The proposed private health insurance discounts for young people will benefit only rich young people and ...
Posted by Michael Wonder on 07 Aug 2018
PHARMAC takes three years to review brand-new cancer drugs and Kiwis are missing out
7 August 2018 - Kiwis are missing out on the latest cancer treatments because the government's drug agency, PHARMAC, is ...
Posted by Michael Wonder on 07 Aug 2018
Government looks to include biosimilars in price controls
7 August 2018 - The government has launched consultation on proposed changes to the statutory scheme for pharmaceutical pricing that ...